Maryam Akbari1, Omid Reza Tamtaji2, Kamran B Lankarani3, Reza Tabrizi1, Ehsan Dadgostar4, Fariba Kolahdooz5, Mehri Jamilian6, Hamed Mirzaei2, Zatollah Asemi7. 1. Student Research Committee, Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran. 2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. 3. Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran. 4. Halal Research Center of IRI, FDA, Tehran, Islamic Republic of Iran. 5. Indigenous and Global Health Research, Department of Medicine, University of Alberta, Edmonton, Canada. 6. Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arāk, Islamic Republic of Iran. Jamilian.mehri@gmail.com. 7. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. asemi_r@yahoo.com.
Abstract
INTRODUCTION: There are current trials investigating the effect of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome (MetS); however, the findings are controversial. AIM: This systematic review and meta-analysis of randomized controlled trials (RCTs) were carried out to summarize the effects of resveratrol supplementation on endothelial activation and blood pressures among patients with MetS and related disorders. METHODS: We searched systematically online databases including: PubMed-Medline, Embase, ISI Web of Science and Cochrane Central Register of Controlled Trials until October, 2018. Two independent authors extracted data and assessed the quality of included articles. Data were pooled using the fixed- or random-effects model and considered as standardized mean difference (SMD) with 95% confidence intervals (95% CI). RESULTS: Out of 831 electronic citations, 28 RCTs (with 33 findings reported) were included in the meta-analyses. The findings showed that resveratrol intervention significantly increased flow-mediated dilatation (FMD) levels (SMD 1.77; 95% CI 0.25, 3.29; P = 0.02; I2: 96.5). However, resveratrol supplements did not affect systolic blood pressure (SBP) (SMD - 0.27; 95% CI - 0.57, 0.03; P = 0.07; I2: 88.9) and diastolic blood pressure (DBP) (SMD - 0.21; 95% CI - 0.52, 0.11; P = 0.19; I2: 89.8). CONCLUSIONS: Resveratrol supplementation significantly increased FMD among patients with MetS and related disorders, but did not affect SBP and DBP. Additional prospective studies are needed to investigate the effect of resveratrol supplementation on endothelial function and blood pressures, using higher-dose of resveratrol with longer durations.
INTRODUCTION: There are current trials investigating the effect of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome (MetS); however, the findings are controversial. AIM: This systematic review and meta-analysis of randomized controlled trials (RCTs) were carried out to summarize the effects of resveratrol supplementation on endothelial activation and blood pressures among patients with MetS and related disorders. METHODS: We searched systematically online databases including: PubMed-Medline, Embase, ISI Web of Science and Cochrane Central Register of Controlled Trials until October, 2018. Two independent authors extracted data and assessed the quality of included articles. Data were pooled using the fixed- or random-effects model and considered as standardized mean difference (SMD) with 95% confidence intervals (95% CI). RESULTS: Out of 831 electronic citations, 28 RCTs (with 33 findings reported) were included in the meta-analyses. The findings showed that resveratrol intervention significantly increased flow-mediated dilatation (FMD) levels (SMD 1.77; 95% CI 0.25, 3.29; P = 0.02; I2: 96.5). However, resveratrol supplements did not affect systolic blood pressure (SBP) (SMD - 0.27; 95% CI - 0.57, 0.03; P = 0.07; I2: 88.9) and diastolic blood pressure (DBP) (SMD - 0.21; 95% CI - 0.52, 0.11; P = 0.19; I2: 89.8). CONCLUSIONS:Resveratrol supplementation significantly increased FMD among patients with MetS and related disorders, but did not affect SBP and DBP. Additional prospective studies are needed to investigate the effect of resveratrol supplementation on endothelial function and blood pressures, using higher-dose of resveratrol with longer durations.
Authors: Turgay Celik; M Eyup Berdan; Atila Iyisoy; Hurkan Kursaklioglu; Hasan Turhan; Selim Kilic; Mustafa Gulec; Sami Ozturk; Ersoy Isik Journal: Clin Cardiol Date: 2005-08 Impact factor: 2.882
Authors: Silvie Timmers; Ellen Konings; Lena Bilet; Riekelt H Houtkooper; Tineke van de Weijer; Gijs H Goossens; Joris Hoeks; Sophie van der Krieken; Dongryeol Ryu; Sander Kersten; Esther Moonen-Kornips; Matthijs K C Hesselink; Iris Kunz; Vera B Schrauwen-Hinderling; Ellen Blaak; Johan Auwerx; Patrick Schrauwen Journal: Cell Metab Date: 2011-11-02 Impact factor: 27.287
Authors: Małgorzata Chudzińska; Daniel Rogowicz; Łukasz Wołowiec; Joanna Banach; Sławomir Sielski; Robert Bujak; Anna Sinkiewicz; Grzegorz Grześk Journal: Ir J Med Sci Date: 2020-11-21 Impact factor: 1.568
Authors: Alma Martelli; Lorenzo Flori; Era Gorica; Eugenia Piragine; Anella Saviano; Giuseppe Annunziata; Matteo Nicola Dario Di Minno; Roberto Ciampaglia; Ilenia Calcaterra; Francesco Maione; Gian Carlo Tenore; Ettore Novellino; Vincenzo Calderone Journal: Nutrients Date: 2021-05-02 Impact factor: 5.717